Omanghana
Scientists in South Korea have achieved a major medical breakthrough that could transform the treatment of blindness, successfully 3D bioprinting a living human cornea capable of restoring sight. The research, conducted by teams from Pohang University of Science and Technology and Kyungpook National University, was announced in May 2026 and represents a significant step toward lab-grown eye transplants.
The innovation is based on a specially engineered “bioink” composed of stem cells and decellularized corneal stroma, designed to replicate the complex biological structure of the human cornea. Researchers say the material closely mimics natural eye tissue, allowing it to function in ways that earlier synthetic alternatives could not achieve.
A key scientific milestone in the project was the precise control of “shear stress” during the bioprinting process. This technique enabled scientists to align collagen fibrils in a pattern that mirrors the natural lattice structure of a healthy human cornea—a level of biological precision previously considered extremely difficult to reproduce using artificial methods.
The resulting bioprinted tissue demonstrated both clarity and flexibility, essential properties for normal vision. Unlike earlier rigid implant materials, the new corneal tissue maintains optical transparency while also adapting to the natural movement and structure of the eye.
Preclinical testing has shown promising results, with more than 90 percent cell viability recorded in the lab-grown tissue. Researchers also observed successful integration with surrounding biological structures, including early signs of nerve regeneration—an important indicator for long-term functionality and visual recovery.
The breakthrough carries significant global implications for the treatment of corneal blindness, which affects an estimated 12 million people worldwide. Despite the high demand, donor shortages remain severe, with only one available cornea for every 70 patients in need of a transplant.
If successfully scaled, the technology could dramatically increase supply by enabling a single donor cornea to be converted into hundreds of lab-grown implants. Researchers also highlight that the use of stem-cell-based and naturally derived corneal materials significantly reduces the risk of immune rejection compared to traditional transplant methods.
Following successful animal trials, in which implanted tissues integrated within approximately four weeks, the research teams are now preparing for expanded human clinical trials. Scientists say the long-term goal is to develop “on-demand” corneal implants that could make vision restoration faster, safer, and far more widely accessible across the world.
Source: Omanghana
